Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion

被引：0
|
作者：
Abduelmula, Abrahim [1 ]
Gooderham, Melinda J. [2 ,3 ,4 ,5 ]
机构：
[1] Univ Western Ontario, Fac Med, London, ON, Canada
[2] Queens Univ, Kingston, ON, Canada
[3] SKiN Ctr Dermatol, Peterborough, ON, Canada
[4] Prob Med Res, Peterborough, ON, Canada
[5] SKiN Ctr Dermatol, 775 Monaghan Rd S, Peterborough, ON K9J 5K2, Canada
来源：
JOURNAL OF CUTANEOUS MEDICINE AND SURGERY | 2023年 / 27卷 / 03期
关键词：
psoriasis; halobetasol propionate and tazarotene; treatment; systemic therapy; real-world experience; topical;
D O I：
10.1177/12034754231163541
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：293 / 294
页数：2
相关论文
共 50 条
  • [31] Safety and Efficacy of Halobetasol Propionate Lotion 0.01% in the Treatment of Moderate to Severe Plaque Psoriasis: A Pooled Analysis of 2 Phase 3 Studies
    Sugarman, Jeffrey L.
    Weiss, Jonathan S.
    Tanghetti, Emil A.
    Soung, Jennifer
    Yamauchi, Paul S.
    Lin, Tina
    Harris, Susan
    Martin, Gina
    Pillai, Radhakrishnan
    [J]. CUTIS, 2019, 103 (02): : 111 - +
  • [32] Once-Daily Halobetasol Propionate 0.01% Lotion for Moderate-to-Severe Plaque Psoriasis: Phase 3 Analysis of Hispanic Participants
    Desai, Seemal R.
    Glick, Brad
    Del Rosso, James Q.
    Harris, Susan
    Jacobson, Abby
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2021, 20 (03) : 252 - 258
  • [33] Maintenance of skin clearance in a long-term open-label study of fixed-combination halobetasol propionate and tazarotene lotion for psoriasis in participants with prior use of topical treatments
    Gold, Linda Stein
    Alonso-Llamazares, Javier
    Zeichner, Joshua
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB79 - AB79
  • [34] A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis
    Kerdel, Francisco A.
    Draelos, Zoe D.
    Tyring, Stephen K.
    Lin, Tina
    Pillai, Radhakrishnan
    [J]. JOURNAL OF DERMATOLOGICAL TREATMENT, 2019, 30 (04) : 333 - 339
  • [35] Effectiveness comparison and incremental cost-per-responder analysis of calcipotriene 0.005%/betamethasone dipropionate 0.064% foam vs. halobetasol 0.01%/tazarotene 0.045% lotion for plaque psoriasis: a matching-adjusted indirect comparative analysis
    Wu, Jashin J.
    Hansen, Jes B.
    Patel, Dharm S.
    Nyholm, Nanna
    Veverka, Karen A.
    Swensen, Andrine R.
    [J]. JOURNAL OF MEDICAL ECONOMICS, 2020, 23 (06) : 641 - 649
  • [36] Efficacy, safety and tolerability of a halobetasol 0.01%/tazarotene 0.045% fixed combination in the treatment of severe plaque psoriasis: Post hoc analysis of 2 phase III randomized controlled trials
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Gold, Linda Stein
    Lin, Tina
    Harris, Susan
    Desai, Chakshu
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB202 - AB202
  • [37] Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
    Adam, David N.
    Bernasconi, Marie Y. Jablonski
    Thoning, Henrik
    Wu, Jashin J.
    [J]. DERMATOLOGY AND THERAPY, 2022, 12 (11) : 2589 - 2600
  • [38] Matching-Adjusted Indirect Comparison of Long-Term Efficacy and Safety Outcomes for Calcipotriol Plus Betamethasone Dipropionate Foam Versus Halobetasol Proprionate Plus Tazarotene Lotion in the Treatment of Plaque Psoriasis
    David N. Adam
    Marie Y. Jablonski Bernasconi
    Henrik Thoning
    Jashin J. Wu
    [J]. Dermatology and Therapy, 2022, 12 : 2589 - 2600
  • [39] Efficacy, Safety, and Tolerability of a Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials
    Lebwohl, Mark G.
    Sugarman, Jeffrey L.
    Gold, Linda Stein
    Lin, Tina
    Israel, Robert
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2019, 18 (10) : 1012 - 1018
  • [40] Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials
    Green, Lawrence J.
    Kerdel, Francisco A.
    Cook-Bolden, Fran E.
    Bagel, Jerry
    Lin, Tina
    Martin, Gina
    Pillai, Radhakrishnan
    Israel, Robert
    Ramakrishna, Tage
    [J]. JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (10) : 1062 - 1069
12345